17.01.2013 - In the controversy over the harmlessness of GM maize, the EU food watchdog EFSA has published all data from its safety assessment of Monsanto’s NK603.
The EFSA’s move was triggered by „the level of public interest“ after Caen-based researcher Gilles-Eric Séralini claimed Monsanto’s GM maize NK603 harmed the health of lab rats in an experimental setting last September. However, researchers all over the world challenged Seralini’s findings saying his data were insufficient and would require publication of the raw data.
Up to now, the scientific head of the GMO-sceptic organisation Criigen refused to do so. But in a press conference at the European Parliament Séralini announced he will publish his data now as the EFSA opened up its data first. The EFSA, which reviews the use and authorisation of GM crops and foodstuffs, in November rejected a report by Seralini which linked NK603 to cancer found in laboratory rats as failing to meet “acceptable scientific standards.“ The EFSA decision is part of a major initiative designed to facilitate access to data, enhancing transparency in risk assessment. “Risk assessment is an evolving science and EFSA is always willing to review its past work should new robust science bring a new perspective to any of the Authority’s previous findings, „ said EFSA chief Catherine Geslain-Lanéelle.
05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.
03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.